0001144204-15-025170.txt : 20150427 0001144204-15-025170.hdr.sgml : 20150427 20150427144344 ACCESSION NUMBER: 0001144204-15-025170 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20150424 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150427 DATE AS OF CHANGE: 20150427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25809 FILM NUMBER: 15794795 BUSINESS ADDRESS: STREET 1: 450 NORTH BRAND BLVD., STREET 2: SUITE 600 CITY: GLENDALE STATE: CA ZIP: 91203 BUSINESS PHONE: 818-396-8050 MAIL ADDRESS: STREET 1: 700 N. BRAND BLVD., STREET 2: SUITE 220 CITY: GLENDALE STATE: CA ZIP: 91203 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 v408340_8k.htm 8-K

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 24, 2015

 

APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-25809   46-3837784
(State or Other Jurisdiction   (Commission File   (I.R.S. Employer
of Incorporation)   Number)   Identification Number)

 

700 N. Brand Blvd., Suite 220, Glendale, CA 91203

(Address of principal executive offices) (zip code)

 

(818) 396-8050

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

On April 24, 2015, Apollo Medical Holdings, Inc. (the “Company”) filed an Amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a one-for-ten reverse stock split of the Company’s common stock (the “Reverse Stock Split”). The Certificate of Amendment provides that the Reverse Stock Split became effective as of the date of the filing with the Secretary of State of the State of Delaware (the “Effective Time”), at which time every ten shares of the Company’s issued and outstanding common stock were automatically combined into one issued and outstanding share of the Company’s common stock, without any change in the par value per share. The number of authorized, but unissued, shares is not affected. No fractional shares will be issued following the Reverse Stock Split and the Company will pay cash in lieu of any fractional shares resulting from the Reverse Stock Split.

 

A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.

 

A copy of the press release announcing the Reverse Stock Split is attached as Exhibit 99.1 hereto and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

3.1Certificate of Amendment to the Restated Certificate of Incorporation of Apollo Medical Holdings, Inc.
99.1Press release dated April 24, 2015 announcing the Reverse Stock Split

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APOLLO MEDICAL HOLDINGS, INC.
   
Dated: April 27, 2015 By:  /s/ Warren Hosseinion
  Name: Warren Hosseinion
  Title:     Chief Executive Officer

 

 

 

EX-3.1 2 v408340_ex3-1.htm EXHIBIT 3.1

 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

OF

RESTATED CERTIFICATE OF INCORPORATION

OF

APOLLO MEDICAL HOLDINGS, INC.

 

Apollo Medical Holdings, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:

 

FIRST:          The name of the Corporation is Apollo Medical Holdings, Inc. This Certificate of Amendment amends the Corporation’s Restated Certificate of Incorporation filed on January 16, 2015, and was duly adopted in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

 

SECOND:    That Article IV of the Restated Certificate of Incorporation of the Corporation, as amended and/or restated to date, be amended and restated in its entirety to read as follows:

 

“The Corporation shall have authority to issue an aggregate of 105,000,000 shares, of which 100,000,000 shares shall be Common Stock having a (1/10) of one cent ($.001) par value each and 5,000,000 shares shall be Preferred Stock having a (1/10) of one cent ($.001) par value each. Effective as of the date of the filing of this Certificate of Amendment to the Restated Certificate of Incorporation of the Corporation (the “Effective Time”), a one-for-ten reverse stock split of the Corporation’s Common Stock shall become effective, pursuant to which each ten shares of Common Stock, par value $.001 per share, issued and outstanding or held as treasury shares at the Effective Time, shall be reclassified and combined into one share of Common Stock, par value $.001 per share, automatically and without any action by the holder thereof. No fractional shares of Common Stock shall be issued as a result of such reclassification and combination and the Corporation shall pay cash in lieu of any fractional shares resulting from such reclassification and combination.”

 

THIRD:       This Certificate of Amendment to the Restated Certificate of Incorporation has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance with Section 242 of the Delaware General Corporation Law.

 

 
 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 24th day of April, 2015.

 

  APOLLO MEDICAL HOLDINGS, INC.,
  a Delaware corporation
   
  By: /s/ Warren Hosseinion
  Warren Hosseinion, M.D., Chief Executive Officer

 

 

 

EX-99.1 3 v408340_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

 

Apollo Medical Holdings Announces reverse stock split

and nasdaq listing submission

 

GLENDALE, CA − (PR Newswire) – April 24, 2015 − Apollo Medical Holdings, Inc. ("ApolloMed") (OTC-QB: AMEH), an integrated patient–centered, physician-driven healthcare delivery company, today announced that it has effected a one-for-ten (1-for-10) reverse stock split of its common stock. Beginning with the opening of trading on April 27, 2015, the Company’s common stock will trade on a split-adjusted basis. The Company also announced that it has submitted an initial listing application to the NASDAQ Stock Market to have its common stock approved for listing on the NASDAQ Capital Market.

 

The Board of Directors approved the reverse stock split on April 17, 2015, pursuant to authorization by shareholders at the Company’s annual meeting held on September 30, 2014. The Board approved the stock split to support the NASDAQ Capital Market listing application. The Company cannot assure that the listing will be approved.

 

Following the reverse stock split, each ten shares of the Company’s issued and outstanding common stock will be automatically converted into one issued and outstanding share of the Company’s common stock. The reverse stock split will affect all issued and outstanding shares of the Company’s common stock, as well as common stock underlying stock options, warrants, other common stock-based equity grants and any other of the Company’s securities converted into or exchangeable for shares of the Company’s common stock, outstanding immediately prior to the effectiveness of the reverse stock split. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of such fractional share. The reverse stock split will not affect any stockholder’s ownership percentage of the Company’s common stock, except to the limited extent that the reverse stock split would result in any fractional shares, which will be cashed out.

 

The reverse stock split will reduce the number of shares of the Company’s issued and outstanding common stock from approximately 48.6 million to approximately 4.86 million. The reverse stock split does not have any effect on the Company’s authorized capital stock.

 

The Company’s trading symbol of “AMEH” will not change as a result of the reverse stock split, although it is expected that the letter “D” will be appended to the Company’s ticker for approximately 20 trading days following the effective date to indicate the completion of the reverse stock split. In addition, the common stock will trade under a new CUSIP number, 03763A207.

 

Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split as of the effective date. Stockholders with existing stock certificates who have questions may call the Company’s transfer agent, OTC Stock Transfer, at 801-272-7272. Stockholders with fractional shares will be cashed out directly by the Company without further action required by these stockholders.

 

Page 1 of 2
 

 

About Apollo Medical Holdings, Inc.

 

Headquartered in Glendale, California, ApolloMed is a leading integrated patient-centered, physician-centric healthcare delivery company committed to providing exceptional multi-disciplinary care in the communities it serves. ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of six affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO (Accountable Care Organization), Maverick Medical Group (Independent Physician Association), AKM Medical Group (IPA), ApolloMed Care Clinics and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care. For more information, please visit www.apollomed.net

 

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of future expectations, plans and prospects for Apollo Medical Holdings, Inc. (“the Company”).  In particular, when used in the preceding discussion, the words “predicts,” "believes," "expects," "intends," “seeks,” “estimates,” "plans," "anticipates," and similar conditional expressions or future or conditional verbs such as “will,” “may,” “might,” “should,” “would” and “could” are intended to identify forward-looking statements.  In addition, our representatives may from time to time make oral forward-looking statements. Any such statements, other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based on the current expectations and certain assumptions of the Company’s management. Such statements are, therefore, subject to a variety of known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company, its subsidiaries and concepts to be materially different than those that may be expressed or implied in such statements or anticipated on the basis of historical trends.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in the relevant forward-looking statement as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results.  The forward-looking statements included herein are made only as of the date hereof.  The Company cannot guarantee future results, levels of activity, performance or achievements.  Accordingly, you should not place undue reliance on these forward-looking statements. The Company has submitted an initial listing application to the Nasdaq Stock Market to have its common stock approved for listing on the Nasdaq Capital Market. At present, the Company does not meet all of the initial listing requirements of the Nasdaq Capital Market and therefore the Company cannot assure that the listing will be approved.  Finally, the Company undertakes no obligation to update or revise these forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statement was made, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. You should not place undue reliance on any forward-looking statement and should consider the uncertainties and risks discussed under Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended January 31, 2014 and in any of the Company’s other subsequent Securities and Exchange Commission filings.

 

FOR ADDITIONAL INFORMATION

RedChip Companies

Michael Sullivan

800-733-2447 Ext. 115 or via email at Michael@redchip.com

 

 

Page 2 of 2

 

GRAPHIC 4 tex99-1logo.jpg GRAPHIC begin 644 tex99-1logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`1P$]`P$1``(1`0,1`?_$`,0```$#!`,!```````` M``````D`"`H"`P8'`00%"P$!``("`P$!``````````````8'!`4"`P@!"1`` M`0,#`P($`P4$`PP+`0```0(#!!$%!@`2!R$(,4$3"5$B%&%Q,B,*@4(5%I&A M8K%20[,D-'6U=AL-L#XY#(2)^'V:UEQI#X:U+J^A946H MF3%H!]:SA#E0%`U!^W6K$.1QQ*SVS$BM%7O^S7+*OOG4Y*@J'QIK%DL_,X/< M$^9`X@*XV:I\:]3KG#$869"23WKM:\2#,%7KM7)+1$M$2T1+1$M$2T1+1$M$ M2T1+1$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1%8<35:5 M;B!3P'AXZ&5K&T-,RQI('R3!X)R@*O6#YAK7E59=/8K(+@)(0#\Y"JJ\$4/S M>'CTUL7@.;E',+[*X-;48X+6/*_(MJXTQ&Y91=76PW%;4B)'<6$"1,6#Z"-U M=X34'P&N_2=-EN;H1L!))^SM4=U+4&QQDUQY<4)ZXJ2^^M1C M00LHBV]A2B6@V!^,@?$#7H_;VVK:SL/F7,;YC6XG*,:*#7>LF9KX,P'8LW7)*4H6AE;Z5D M44UM*0#3YCO*:#46F?=VYHX'UK)`B?\`=H1X*\7$@=4@&GQ\_P"C67;7!EH" MOOR[2:T^Q76E;D`_:?#[]93N*^.8&'*."N:XKBEHB6B):(EHB6B):(EHB6B) M:(EHB\VZW:W6:(J9<[C;[9'"DH^IN47`RL)#J4;W0DDI2E1(1M)`W5IU\-$78T1+1$M$ M2T1+1$M$2T1+1$M$2T1+1$M$2T1>+=;O;+4IM=SN,*VMK%&ESY<>(T\H$[D- MJ><1O<2*&@^.O@MC,_,">RBZI[R"TB+I2`>]>.,[Q4I*QD-@+:7$MJ6+O!VI M4M*U(0H^MT<6E"B!YA)/EK+^1-&FG:F M96._[$%*5@;TB0MT*-&?3IMC_P#>-?#5W/MA;VYM",KW"@"KOYJ5\HGC)="T MU)KA1.TX@Q[)N1+FS;[/&D+9B>FN=+0@J;C(5^\XNH32@\B3JL]PBQTQA=?O M#*#@1B>ZBG>BW%[>T^18Y_\`=*SSN"S/DWMMM[3^+<+3.1+:60Y<\QGW"0BR MVI5/WXS464I"01X`4U%]*CT'6Z--XR"1WX%<3(3C6(1;:RY3^"BT-I:V@]5INOI?4`*_#U;J/'4Y9TBM[Z(/B MU.1XIA^[!]'WE7<6^=3M+AS;R%T6%*EY_0GA<2>ZS8+O(CV_E?!7\08=4PTU M=K1<7+W"4I:T(^H>:?CPOIH[==RJ5VI!\=0[7^D.JVK'264&3R-%>UY[/!%GP[-,8SVS1+]B]YMU^M4UI+T:?;WTO,.M*2%!:30*` M(/F!JH]0T>XT>Y,%W$Z*8?A(H5:6C:XS48@Z$AQ/8:K,VBDH!32A)I3P^_6O MJ'8MX+?.S5^+!RN:+BK:G6T`%2T@*6EL'QJM9HE/2O4G1%7N3UZ_A\?L\^NB M*A3K:4!Q2P$$A.[RJHA('WDG1$B\T*?.GJHI^/S)!)2:>!`2=$5`DL$)(=31 M1"4]?$D5Z`]?#1%>J.G7Q-!]_P`*_'1%P%H/@I)_:-$5"GV4+0A3B0M:2I"? M,I3U)Z>0T17=$5M;K;8*EK2D)!)J:=$I*S]IHD5T1`[_`%`&17.S^WUE%UQV M^7"TR1D5J"9=I=6S+<:6'$*;;=0MM;52H=?'1%%A]E/.K%'F6 M7*'[G&MUPD1VYPBKM:6`IMI:`HC>?'1%E/Z7;*,DR&_]W@ON27F],L6OB]Z' M$NH=3U*DCKYI5M4*>/1736)-?6EM,RWGD:V>3[K3Q/@OH:X@N`^$+DR&` MHH+J`H>*2:'KK)D>V$!TI#0>%5T"XA+_`"PX9^Q5^HW_`'P^.N3/C:'LQ:>" MYND8P5<0`J?7:`*O430"I-?+XZQFWEJZ8P->TS`XCFNQH+VA[<6G@N#)8'BZ MD=:>/GX_]>LP1O/`%8TEW;0FDKPT]Z2Y+"-N]U"=U-M3XUZ"GWZ^97=BRXV/ MF;GB!*D%0^X$`GX>)UE,_>,\QF+#S7#([L5*I#"!53J$C[3KH9NT>)^X:Y&:)IHYP!7:]CHXC M,\$1#B>20DL%.X.I*?B.HUD>5)6E#58\%Q!,^VTZ4N-DIW#P^W5T=%=$TS7M1NHKYD<@8QI`1Y;>(?"`:>DT]*H!NY-:.D/N MJR^6+EC:YSS;(:?8IM4MXQF'''".BB5;?$-U-/VTUX%M(C\R2.97N>0UC/@H M[WN*SYD+N;G20I;<.Y8GB8A*5T'Y41U+^S_Q*%=>K^CC*:;D/WA(X'UKSOU" M?DG)[EHGC5J;E636O$K&AV7>+O)CQ(X%5(]>0L(25_9J>;R=_3M-GU48&!A= M7AP[^2C.VYC>W,>G<72N#:AL^H\S$;>ND[:#(ESEI" MEC>/F*4*Z4KKQIN7 M]1)7W)T^]DJ\,P)=2OHIQ5+;KV:71BYC9@7'\/!"F9PUJJ3'CD*EJ4I]MY/R MQMI.]L`CIKT+8ZRR_MP`X'#MJJGNM)?93XM(IW43K.UOG++.`\LBJ$^;<\)F M7)N'>+;(6M:8,9U>Q*HS9)2A".GAJG-_[5BU'S)XV#YEPP<&U*LC:>O&Q\E^#=(SNO,]U;/M)W6\C2 MU[#0@X&JO33[QM_:MN6FH=WU7?N#H9C^H2TFBP?4>-$MT"E%P)_PBT!-0GI7 MXZQUFJ'-[E?O[\KXIRYEG`7:?'L.)6S"KM-LMXY#NI_B%RR=^&E/K*LJ$EG^ M#E#JB`O<[U&B(4LOW2O=)QJUVK.+KRGRM'Q.>](?@R9ENGRK1>9,@%J&Y)D+ M4PVW$9E4`!)W)&B(\WM"^]SGW"^O%L]M-+0Q='X<=PN M0Y\!9D>O._)4`YZ@J>E-$3A/?'[]>XKL@MG$<_M_N]GM,W*YTIO(7+Y8S>(L MIF.B1Z2VZ2HHW(9;%?[6B('>$_J*^[>W<7\DP<@:Q[*^6KW<+=%XYNXL#ENM MEFL2XSXOLA<),B4IV0U,#9;H02*Z(FDX_P"]A[B^(YDUE(YFGW!K^),/HLN0 MQ9-QPEZ8ZHN28CUK>=BF$E831`*E;=$4U?VP._FQ]_?;ZQR!+BQ;#R/CUV38 M^0,=AH#2HUT0EL1[HF*%%3-MN3F_TZ]#L/71$P'W>O>=G]FV4L\"]OUIM61\ MS/VSZV\7JX%,JUXON+GHQ9S`ZE]LHWK;*DDI(T11NW/=E]T7-+?<^1;3R]R5 M(Q.%(<5<+[B-KG)Q2V;5E4IM,-M;C:XL5>Y)/J``)T1$]]MSW^.5[YRWAG#? M>$_;KWBV93H6.V+D6TQC#OEAO=Q=1<B_1%N/%;-U<<::55::)=W?9HB*Y^ MH/\`15[>&6/LN)=$C)K&OUD4V/!"4MI=;()3L4.HI4&M=$45/V1_^9/V_P#^ MGT?ZNF:(BC_JB_\`B[VR_P"S>7?XVU:(LH_2PEQ%^[NZE"D.67BSTP>GIMHF MY)]6I:J^:%#:/,C1$^CW=/>CG=F-_5P?P#!L^4\R/01-N5[ND,7FU8B9!6W% MM4VVI=9)FOJ0:**T[-P-#HBC>.>[#[I>8P[MR%9^4>2W,;BS&G)\ZRPIHQ:% M.]1*WV6H[96VU;H(-5#?0!)T1$\]M?W^.6;SR]B7#W=RY9\CQC*YK-FM7)MK M_+?QRX7"0(,&7<&U%?\`%%3[DXF.?G;]$.5Z[>I%(Q[^N=N0^#.&+7G7'#]L MC7MS((\#ZZ;BM#A9/E:P"N0$D]O%;W<74G4[&Q,KO,&!_'3W)W.% M>[7E%KX6R&)E-KM\[ER$XY%Q2[L,*>LDEIU`0B9,BIJIYZWN#>6]P+^ZE4TU M7&Y/I^L[358[^UE9'97&=Q>V&C69:$"N;'-P"[MN=8;B[T]L1#G2M`'\6I/^ M%,ZN/N"]VJ[^Q-E\C3+9)B;9:+*W`>8QV9Z2C+^F2I;P]5+R54*J>!V^6IMI M72O0;JT(A9!)(UM"X1UQ[>*BNY>I&J078QE#2?V_U(XG8-W87#N;PNZ)S!N` MQGV)34L7%FUD%IZ`^RVIB8MOQ#?U+NT_:->=>H.T)-K:FZ/'R#B/ARBO9Q/+ M%7;TRW]-KEHV"5KBXX5+ZTQX\/0M==]_?^OM^NS7'7'4*-=>1)5O^ID2G@'( M-K04_P"'2#T7UW"I&MMTTZ6:=OZ7YN_DCCA8X5+X\X('?4>"T76+J#J^T'?+ M::V4ROI3*_*145["A+*[W>]*\0;AE,?,\G1:0ZV[,?MMKDO6=A">KK<9U+FP M-H5T5\->EM1V#TLT*!EC*=,-P`!BT-/#`TJJAV_OWJ5J\1N@W4?)%?Q$CUT3 MUNSKW*LUR[D'&^->;A:9=MR20W;;!E,57I.^LL_(BY)431:B.M2*'5*[]Z0: M=I6F2;NT0QO#W!N6..GPD&IS5.&'8I1M+J;J^K;H9MO6Q,&`YB9)*T(X?#3W MHLO.J8VUME^X=6 MCL86DDG$AN:GH7HO>FX&:3MR6Y8X'*!AFIR\%&_RGW%^Z7);V_>K=G*\=M[R MBNUVFSMKA)B545(#]M2MU4H;2`>HKKUQ#T@T2PT9C-09";H-%7.CH37TKS!H MG4W4Y)7F`RYV+7-D`XT7Z$"8/S,'@@S^YA@#^06'"N6K(PI\8E*5:\L6P@K=;B2J&WN3J= M1;XJ62E1Z4*AUU?W3+5!97DEI(=$7*;_E(QRW29[[K9`>"D8I:24I!1U14(K7Y=W15/OUY*9!''A@0O3ERSS M&G+Q7#4=+((2@!/4TH?%1ZGJ==CF1N%`!58=O"]KZNX+HW2UP[S`F6RY1VY, M.8PY'=8?3N:<0M)24J'2HZZ[+)SK"=MS"ZD@/$+(O;:*ZM_*>`4`GE[B3^3. M2E1ULL MN[24[RTI=0!U.H:I2H;X_3@;.^M5QM,V[ MN7&=!E2';N@['8ZRA5?ZM$3\?=F[N.Q*Q]D68]O]CSGC#-LX./6#&\:QK`EV M:XW"RWBS^@TW-#MZP?F_O!R7)^1L6M646?CS`Y5SMMLO,,3(3%^;G6YN!/2PJC9?996L"H M(()J-$3P_P!3+V\<>XG+X/YKPS&+-C4W(&+[9LMN8MR+U](NW"T?6,14- M1RJ*VXX$E*$JZFM=$6%?IC<[GV7F;N&PIEY0M^2X9:+X(:W3Z1=L#=T>]9"% M$D.`R!U%/MT1`4[R^29?,G=;SOR7<)LF8]D_)MWFMO..J=<+<:8FT);2:T2A M(@TH*#[-$7T*^QOM8XNQOL"XKX<5B]@?M68<5O-7]Y=HA.JN3F5PI4B2_+=4 MRIU;C:;A0$*!^7IHB^*^=N4K-;$.0#QSRAEL"QI:JVY'38LCFHM;K M/[P+$6.@H\:`#1%,B]TC+G\\]D/B7*Y;CSLZZX3Q4]/=?7O=D3CCMO$F0\H] M5.NNI*B?,DZ(H\OLC_\`,G[?_P#3Z/\`5TS1$4?]47_Q=[9?]F\N_P`;:M$6 M1?I92I%V[S'22$HQ[BM8_L['LM6HBOQV_P!6B*.AWM@JGTF&4%/C2E=$4YGN6RQWD#VN.VW+ M);KCDV\X;QPJY27UE;\B)PK4 M*I>K&GPWNF1OER_!6E?8A\=@F`8SR?W-8-9,LALW2U-$W"9:9[6^'C^NEK?Z7MZ*X\TT##RIS"\_=.]M66H;D$9R'X^P_I1(/=[X M]Q"S8+QS?[)CMJM=[8NQMHN-OB-Q'OH4AH)C*#(2VMM('[P)^W57]$+G4]3N M;JS,[_*!:X`XBIK4^E6IU@V?866VO/:(VEK'#@1PI3FF0>V1QKBW(WMA=D+`1RK[TZ;W@,(QG&Y?%=\LEHMMKN5U5B08X?BMN):2E!#;KA(Z5U'/INW/=:R9+)Y>Z-SJT+LWZU+NK.S[#3G1W#& MQM%,<"/>O"]FQT(Y5YN6XJC4?CBSRMM=J=Z;\"I=/#>4CQUU?4;;"'5K>!K: M.?+3AQJU;KI%%9VNC7-XTMSPPN=A@<*G!#5[ET;$^V_"N/).88/!ER<#CHO]JF M""N9_&YUJ2[.]Z:=OB^W;+U=.T%MUTQ;!J#VR3ACB0X8\.Q>6KNY2OG?VH7$^TAYM0)`VM3QXC%:8]J+B*PX^%6A$J,FXL)D-1G;QZS4%Q#2_P`LJ9=CDIJ#J>_41NN^T*"/ M3K9[XFRL;6A`J#6HX5Q4&Z/;6LM4FD,X8X`NX@GWK/\`W<^&L3Q2\\<\@XY9 M[=8W5F-?ZC%R_E3*81F]W> M1A3XUU^>5@!X>YPJ*G!-GR:XV M:9#O=IRB(W=,36YP%P/VQ^B75Q6^NV4T=I0KRIJ?VEA<0P17$#Q\U M$`;GP?W%7QS&WVK]Q3DN/2)-BOR5[)$ M$@E<6UW-EP^J[[=.UO[H&M.2M)KV_B(]:L-R4K6MO<@J;("D! MQ"E"M"-R?%/0^>L*V-\Y]7AX;X+D9(.3VU\5C6:9MC>"61_(,IND6T6F,4^M M*D.H2$FH`2A)(4XI1(Z#KJ16]I/*TB<.H2/2J!^]MZ?]*:F%UK(N6Y6U;XD+3V^GM@.9P!] M:>YVD65=IM^9?(4(G2+<4NT^2L9$A"A0^*B'-49N\N.M.+G9B6-5F:`6G36Y M&Y0''!;\Y@SF#Q;QIG?)E]=<39\'QV?E$QIL(!/?KK<1,1*?8(2IXM*2*U'0C1$+3VPA3OI[;@557_.T<+"*KC@AI8' MT[_5+Z2FA402`JHT12(_U1]/Y9[&B(!')=NFVCDK.K3*0XQ/;SO*VT-N5* MD[)*]5:DN(V?PZ,A_P#-3\A5 MT)IX@:(OF?\`>S>+?<^Z?N'N-OD)EP_][F='U&D%(46+U<;:ZWM/B424&I^& MB*5I[A;3K/L/<,(=_'_)W&JE="@)"[+"4VG:JBC5L@@^%/OT1`8]D?\`YD_; M_P#Z?1_JZ9HB*/\`JB_^+O;+_LWEW^-M6B+(OTM8<$[O/4I-&U8SQGL5N!W* M0K+MXV^(IN'CXZ(HM/*MK?M'*O)4&Z1W(K\#/^E=4$J4X8XOQ60$-+"D)2]9(J:DIZ.=304\"-$7S2^^*XQ; MCW9=Q-UAONK0.2\]9_;(6M?=EB.[TPE%L?],A-"#1L5)/CTUZ`^H.>\U':32QY:&,-:XUJ M0O/W1ZXG;N\"1]1G1)/>+33BK`"`$DY$NI\*J&SKJDOI\N+]VOOL8Y"V:3*, MU,.?)7KUUBFGV>\1R!I#7>P)D?M&*1_^D'VU)_-3B%^<*QX*3]/^&GB2::NG MZIIK&+8D%J(2;QKCF>#][`5PY55/?3YYYUAUL]]2P`UY&OZ$XWWG5!43ADE- M%JF7Y5?()^B0`*?'IJN/I&;%+J+SY9;@.*F7U&7,VGZ:Q[7$D]BU=[.\5PO<76MD^-2'+YLH#TIXZD?U25@W):N9P$HX2H;6G'J'R'EJH]X=< MM$@U&:"31YI+ADI8'-D&.4TS4[U*M!Z):]>P,OX=6C+]A!,I)`/=2O%=+W;,=AXSB MG;5CMN=7<(UHL^2V^-(0DO-KB,L6="GE.(!3\P`/VZB?TV:A-J>_I9);>6,> M5(3F'>%SZMP0Z7MMD3)HY,SF@93PI7OYJOV79C#68IJJE/'7AK1"VC",%[,O&/9.ZN.)3-\FO+A<<0"A`JIQR22%%E(\62SU*@[X M^!\-6YIK&RPAHIP4=N[@QU[<5J"/R9DF%W!4W';X[;IID![T'U.*MY82:J'I MIW%&[X"AUV7FA17T9BE;F8?'W+60ZHZ&X:^N(=W+9['N`\BX]%3%F6#'+ZIL M;?JJSV5J^\%Q`U'9^EMQ=R@V+HXF4X$/*V5SN[Y9ASDG_E6`95[DO)0CNHLV M&XQ&>HOU9?JS%2H;BDT"V@'RTX4]"`X%:W-AT:O?.8^ZFA=;C[S:/%?#L42N MM_N^)L>?-7`_"FJ8QE_+_=WS5BF-9-EMWN]N-[@W>ZVX(.6D*70K60*DG6?N;:NE[1L1>V+&QS2$MJW,3PJ,#7"J[]"W#=ZY M=/AF6\M1205!?5(-?':#J#ZU<_-WQF M_L@>I2>RMQ;6XB`IC7UK6'>?@5QY2[4.X7CFTJ?1; M0IJE#O%.E.NM2LM?,'XESB7V^\_8!R//LMR=OO#W+EARA5NDNB.^O^4K^AYV M%(CN*0M+D@1.B"-QW=-$4EGW$??CP'N8[9\BX'X(XWS-.6YW;+=_-5]O+5OD M6VR6M!:=O#;<",E4]^,VE+FYT(4EM/4D4.B(&'MENQ;;WT]NJI+\:#$1GL-I M"7'BU%9=?:VI0VY(6!68^OI6`-$4B_\`5&K+>-=N2]ZFJ3[I\R6VW5&A MF%24H=2IM1*?B.@ZZ(H\/MO=[V1^W_W`L0)TO&KI M(CS'!;9KKHL\:6'XK>T%0H=$6[_=A]SA/N+YSA#F/X7=>/./^.K?<&+/;KI* MCR[P9%\5%=EKN)AN.L./)7#35:?EZ]#HB-;^F2[=[CVTY-VR][',-KEQ M)<#`>7/\`5"DIJ=M.FB(R?:[[_P#QKQ+V M2VWB;.L*R>5SM@&'SL8QR5"D)-FO3RF7TV>YN/!S\KT4NHW))!&WP&B*./P[ MQUFW=YW*6S#K%`>G9+RWR&;U=_I8CSS%O;OU^,V]J?#;:O2:C0)#JBM5`5IK M4Z(II'O<8/&XR]J&W<=1?2]+`8N!8DMQL`(6G'[5%M;+ZB*)'K-1PH_:=$49 M/V2?D]R?M]W_`"[[^@HW?+O_`/;IGX:TW?LT1%%_5&+2GESMF*E)2!C.7J-2 M!1(=M(*C7R!(ZZ(LI_2PL-F^]XX4XL+=L?$[+S2ZA#39DY6-P"A0%Q*SN^P: M(@R>[IVSY9VU][_*5JG6Q]&$YQ?GLHX_NLB&\B%-Q^XJ"Y#0DE`9=F19@>44 M@[DI()Z$:(C`=HWO^<;\2=D5LXLY%QG)+QSC@.(W7%<8F6UU*(5S?3]6+`Z^ M^M0"0P'6TD[@`$Z(HZ?$?'V;=W?LE8AQWKB[;7\GO: MW[LJ<8R7O2BQX$QQ?J*HC>/$Z(IY'N'8"SQ5V)<5<9QMIC\?L8=A[*VQ1+C6 M/8Z;6V\*``EU$8*/VDZN'HQ<,M]Q2O>:#R>VGXFJJ>JT;Y=)8Q@-23RJAK>V M2H?_`*OQ7:05)MCY(!!-!Z533QIJ^NK]Y#=[3>UI!(9VCN[%Y]Z:6<]INELA M!#<_8?>B5^\8L*XFX_43M"KLZOO MENML^2P&I8>5?8F.^T=5'B@E;!VD@]0%`=-6A]1=Y!J>WF M,:03YG:#[%6O1&SDT_5S.\$9A3@1P\4Y'WGJ*:X;2CREWQ*0.M:PT=!XUJ=1 M7Z:IH='O)7N(;C3C3VJ1]>;676;5D3,13O/L6N?9I.WEWFIHU"SQQ8P4_O`' M($]=OXM9WU):A%J&HV]PT@@/-<1^SW+6]#=-ETO3+BW<#F?'3@1Q/>F7=\_# M5WXBY_SN#.C/-V#(IK^6VF[%AUN/(DW"1]4Y%$A20VM27'B"*UU8/2G<6F[N MTN.Q91CF1!GQN;R&4TH:XTJHKU`VU?:==NFB::9B<&NYX]B?1PM[G>-X5P%% MQ#+K+=%YW8,9>L-F$0,F%+CB/]+;E;EUIZ2-A5]VH9OKH7Y6MNU."YM!9/>' M9/C)[78]ZRML;^U33],^1>)O/#2`-\@=P7.>/6*U.WB9.RW+ MD7"\+^H?6W:?\M$R4\XJ(K\J$D(*2HD(ZC4SU;<&W=L;&?;B(^:P$5:\6EV-7-P^P(YGNG\.S,A[?<9RBR0I-TF\?72WQTQH!HZBTS&4 MMW(N%1WA"?I$;B?VZHOH9O*RTK>!=*"#.UPK5HXGG56#U4V5J,FWO-SM<(LM M`&NY(,?:!W,W#MCY(FY6S;EY#:)$27:,FL,9Q$53"'&]K#T9]U3275,E:CT4 M:'5U]8=H6W4BZA?;RPMD8QH#G$GF:_=*I[I]NV\V7')))',YI&DX8_A'#%-C@^G M_NYR=[:=G\T8(CP_^(Y%=W?!_9D'O4U7/<,CYM8Y-M<6(TSYS%D)\4J'X03_>JKUUX&L;UUM)7\"]T MW-BV0%PIF([T*?E;%LEPBZ2K;>H+K;(+AB7!EI2T2VTFBEK4D$`IJ/Z=7#MS M4&SM;E-13N5?:O:F(&B:GD5V;ZD%EU(J5[DC>!Y^(J#JV+-K3&)#PHJ]N2Z. M1:*R&Z-)]9QYU:$'<6FT=2?@*#4JTZ:$#,X%1[4)GOJP+!+)BN6\D7N%C6'6 M>XWZ^7-U+$9F#&=0S!:<5M+]S>VH05(ZFI)Z`:Q=>W7#I4)<210?V?>L?3M! M??2@4!!\?=7^"TW?9:MQ#,VG/AQYIUO\`*;2UDK8] M,A0)"1_V:A4NJE^%3]BFT6GB.F'P^E>K;L2AB5Z[S=$M'FM;+09O(=PQJ[8;E5]N/\4OQWMV@9>U8N/W+Y>\\Q^[8;>+UDT^?>9"+- M?(CT&HN46T`*U`3T^&B(9GZH-OZ?$^W&*E?Y+UVN2RS)6 M5O;5_6[TB0HJ4DU53\6B)C_L$=M7"G=1<^Y3BSFO$(N48NK&H0BVV6GZ>7;7 M%^D/JK=.;V.MN)*JI4%"AT1')L'Z=GL%MUWCW-VVYC>;?!N(G-V:3>YS944. M[TP9$E$T.2XB/P_,I51XZ(C8<><9X;Q-A5EP7CK&K9C&*6&,F):<=@-MLQVV MT-H1N6I`&^71'51J2?$Z(M(]SG9SV[]X.)##N=L#AY@S;W`[`GT-MOUH=-"@ M1;NP6)*FFE]=OJ%/V:(A33OTX?89)E.)8?SN&)#HDM0DW:8XE#0.XLB29BE@ M4%*[JZ(B)]I?MR=J?9;%EO\`#/',2V9%)]-F9F5\K?[^X@!-50)4U4QZ"E13 MM(;4GI7XZ(MS=S_:WQ5W>\73.(>8($FZ89<)C,^9%MLQ^"_(>CC\OU7HKC+@ M57RK0?LT1,L[>?9C[)^V+E7&^9N*,,O]OS;%GOK+/+NN57JY-1G@A37RQY4] M]"04.'IMIHBV[WB^VMVP=]-YQJ]\\8_>+Q<,,A3K5:W+;=[G;T-Q;FJ.IY)] M"0P#UBIJ17PT1>SV<>W7VW]B$_/)_`]ENMI5R+&M+&1_Q.[S+FTINQJDKA@& M9(?4DUF+^[1%L[N>[-^WGO"Q5.'\\X#;\Q@Q-KMMN"G'K;>;8^%;T&!>(*F9 MT=M2@-Z$N!+B>B@1HB$C,_3C=B:GWW(S^;VYIYU;B+?$N+KS3*5*)"$2)DL. M*"0?,^6B(C_:/[3R&$-7#+;P\;K?Y"$@`E,J0Y)X'&XV'<@Q'KA96)PN28[%PEQ'"ZAEQNI,9QLUHYTUM M]%UV;0KOSX"/,]:C6=&CU>VR2#!OC[EH?ASL+X!X3S:%GV!6"9;K[ M`C/1F7Y5WN4JGJ*0:EN0^XVL41X'IJ5:WOW4M3L76=WE$9[`.'8H9HFQ;>QU M#YF,"H-<2Y;@Y^[<^-.XZPQ,;Y#MLJ?!MSJ93*8TQZ)1SH0/R'D*\1J/;9W7 MF:SRE]:XJ3;FVW%JFG^4X84(YK6W"'97PGP%E;V=X%8IUKOS\15K>>FW M67+2J(XG82$O2'4A)!-.@UO=R[WO]?A^7O3&6@UJ,/0H_H>TH=':V6,8^)67 M<_\`:GQ+W*)Q]')=LD3TXU(>=M0CW.;;"VN0@)?(5">94]O0`**)`U@;=WC> M;>+C9Y:N/.AQ6?JFV8M9(\T5`\1[%X/`G9_P_P!MUXO&0<;VJ9:[IDMK19KF M[,N-PN"W(<68J8S13[KP24+H1X5TW3O&YW&6MO\`*0#RH.(H5ST3;,6AR@Q` M9:XXGWK9_+W`W&'.5H39N2,7@Y#%0T4QI+BC'F,+((WM/H*'$FIKT/CK&VQN M?4]H2>?H4@93&E`_VU6ZUW;UEKT1;*T%Q':?<]2 M,Y<)4\K0XI1#+;CS[JHR*=`4E/34TN.MV[M1/EWDGPGD8V`>NE56AZ86D5QF M#0&^+DZW@WM:X>[=F'O]VV(MVFYOE3;]TGN*N%T=:<(+B1,?6^\VRZ0#M"@/ MLU%M8W7\FC^7XY00,>_F5(X-J1[>C9J-BW_P!DN#:BKC3P."W_`'6S M6N]6V?:9\")<+=/0MJX0[B`_'>;<3M6"'IDWM;]L>1W9Z\BV76R_5O*<=@6Z:\F*M2EE:JI]=/R MJ4KPIT&K'CZG;HM&#R7M^`#\(Y>A5UIG3;;E_;/%S%F!G;E* MPF!Q^G#VV;/&F/W+UVY#S5PE2W([;*S*FH<#WH*0V*(W;:^777R#K%N+5)'Z MC>OS2-:(Z.#6T`-:@#"N/%:1G271],E-KIK`V)[R[!SCCWDU*Q-KVQNV1JWS M8:+!<_1GS;7JBNTD@TJ!K4'J;J!U`7N9 MN8`M_#P)!]RD_P#^>VWR1M*"I(/%W('T\T2H(:%1NZDDUWFM2:FAK4==0AHH M3EXJPR7T[EA>9P<$FPU1\T>Q]F$XRZE3MZG0H2D-FF]33\MUO:/B0>FMOIL^ MK02B336R.>#P:TN'I`!JM/>6^ERM(NW,`[W@>],-SG@/L[OTB0Y&Y@P?&7W2 MOUP.1,<=#9/XBEJ1>$`4/D=3R'<74EC*1VUR8O\`:O/VY%&9M&V2\_OIX0?] M=H_S+75N[8>RF).8D9%W!QCMTQZ*+=Q!<^/[BZVA2796.9) M8K]=UI(^8R)MOF292_E_OCT&H;N"_P!UWLIEUR.X97DZ)T;?40`M]I>G;5MZ M#3I(7&O*5KO8XIP:&T``!1-$@`A9)H!T)-:DZA#8[82N&OAKS7-H:!1O!<*`-*^2@1UIU\OOU\7)=-E%O+KIC&.'@YND?3+;#A<'D^& MSN)^Q6B*\6V3TW4(2L*HY11"A16X@U-!X5\-$5#K8HC:MRJ=NP)6KJH``%1! M^9.T=1YZ(@+>]GVC\4=T5IX@A\G=U7"W;0C'I[2RS=8W%O(N"9Q M,M4=);++MP8Q:]721;X^T"A<2A)/GHBD6M!!9:Z@#8"G:0.G2H33]WP\.FB* MJD;Y:^E^*B*E--_]CK^/[NNB*A349+>UY04C?NJ^YNZ_`*6?"GEHBO!*"BB2 M-AH1M-$@=*;2.FW^K1%;]-A:0$*2E(56K*]G6O4$H(KUT1=I2=M M2H5HHB@Z^6B*VXB,4/!PMA"@0[58"0/,DUHD]?'1%REIA`<.[E@L!1`]0QUH2X$ M@BFY39W`5T1%*GIKNE;$YE)",E.U?&F0?=JK26X@4=JF]WG1P M$_W:ZZ(8K1LF:$@R=QK]BYO?.64>#D\$G$0J++I9VD("@XM&P`$^F:*-!UK3 M7=(V$DF0BO>5TN-8\KOX:MK9@UJXMNJZ[-[P^7Y:'T05?+T^&NHQ6M<2*^*^ MQ%S?X7V8KL);9`51500`:N5'@*>?3PUP,-F3B6U_O(\N(.?@J5HB;`%EK;Y% M2T_U$G69;!K/_GQ/=BD&=O\``J?#%5-H8`4&BDU`W%*P33RJ0:_=KG/5S:38 M-[\%R>Z0GXZU\%06HI)!4G=MH3Z@W;?B>M=1]UEH9FS.>SS?]0>RJYYYZ<#E M\%U4QK8DU#C1HE0H9"5#::5)!7UI\?+6T\NUH*D4!PQ2Z?-)`YET*0GC44'K M780U"2`$J;/7Y270HU^PE1ULBZ<\C2G8M?8QV\+"+(@M/&AS>Q GRAPHIC 5 tex99-1pg2.jpg GRAPHIC begin 644 tex99-1pg2.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`.@`Z`P$1``(1`0,1`?_$`)X```$#!0$!```````` M``````@"!PD``0,$!@4*`0`!!0$!`0`````````````&``($!0<#`0@0``$# M`P($!0($!`<```````$"`P01!08`$B$Q00=182(3"#(4<8%2(_"1L3.AP>&" MHL(5$0`!`P,!!04&!@,````````!``(#$00%,2%!41(&87$B$P>!D:'!,A3P ML='Q(S/A4L+_V@`,`P$``A$#$0`_`/OXTDEC<4E(]1`''B33AU.N4KR!RMU* M\+0[5>=.NULM:`J?.C1=WJ0EUU*5KI^A%=RJ^0T^UMIJ$`$U3))HHAXB-%CA MWNVW"BHSZ5[N`-*5\N/JUW?%)&/$#1<&7,-.I\Z#IUU&=.6VYGIMK2B3NM`[98VU<7$H=N MMR>^PL\-3FTNRG$J)>6D<51V$H))I2M-$'3^*ES,C7T(8!4[Z5W*HR=[%:Q@ M\U'&OP03VON)<+Y,-QNLUR7*=>62MPEQ#8<.ZC84HA"4I(%!RUJS>G8HH0UC M0#3AO0>;TW:OR71MO>X*TH.E3Q_E37(R,+:L-3127L$9#2=JRU MX:]:2X5.Q,5JGP/\?EI]%[0<5JK52O&@H>7/GT_'5==@MLZ-J1S;N].C\41/ M>HA/FKG+Y[RVO&42EB-8\7BO!@%81[MQ=<6ISF!O*6AQYTU]#^FF.B;A3.\5 M+G#X+%^K[^7[QD+30#F^2YCM!"O6>W^!CUE0MV2]13[B:EN'$0![LY\T(JW2 MB$D@G5YU+D8L;$9'D-:!L)X[J>U=^F[;[SPD@NX5VT1YYMV0[@1L(;@=GLY@ M8EE[27'IEZO%G8NS=T64;1"0J2E9MC(<'!:$E0-#K'X^J;:?(M=EV.DMZZ`; MNTZ(LO,#>?9DXI_ES4V5V?FHHLI[L_,+M5EMRLF29[D4"]PWT!Z++:9EVQYO M=^W)MR'(WM2H;YXA0I0<*<-;CB,+Z:]10M%G;`W!;MI4T*R*[OO4'"79;=7' M\0VT/#3BB]^/WSRO4JXP,5[W08[)E.MPX^96UA,=I$HK#8_]FWI]$=I:B*NH M-/+6?]8>E9LA+D<03)%%XC&WQ.II0-&W?I2JT3I?K5U\^.SO_P"YYIS;@>TZ M*4^-,8F,L28SJ'XTAM+K+S2T.,O-+&YMQIQ!*5H<2001TUC@[_BD90R,@Z[5"M\^[1*M7--?2'I/<6MQ9OQ4QI(7`@'>#O]]5A_7UO-;&/)-VL!=4^Y%Q\` ML388[:R<[=0ERX9-6OI#&9>*&9 MMU.:-N/F%CK,B5B+[,:VON**I#UGDU7% M#A43N2P?2#SH-?.G7>&BQ68DR$?TSN)JM9Z4O9Y;003[#1%U[K/_`'_T_'RT M`^/_`*]B+/M&?%<+G5Q5!98.X)WMN;#0\Q7B>/31%AX898S%)6A5=+]R,7NV$9NR\_9[HI,QJXQ4)'4^"%L_;6V4QSK&ZKY3M[=A%.W:GF^)..W+".SED MPZ[7"TW239)UQC1+C97T/M7&`J9[D2X/LU#L:3(2O]UO;Z55T)];SON\VS]TS^8]V,"M^06_`'[U%FY5DK4V)"L<%8E2@ MRB(^J3)FH:*PQ%:!`)414ZN(<-D9&-OW,PZ::J`^^LYB^PE?5Q M;7PG]T#KF#!3DA+3#;02\YL*&SM`2XHIJ"2"#36PW&0M;.6`EK=HKW[T0_QVQEVT7K(Y*$%##EOA1BK;0>^E]*R$FG+:3H'Z M[NQ?Q1PN/ACT(U/>B+#,^TJ9D-2WHX2*EUL(.YA('%2B=7-C/Y%R&NV-)4#(AK(>;>`H\,LO#Q6ZVX M'&EL+*7F"DH>;>1N2NJ5[5`M_P!#K< M/M:F(T?W[]R;7)_D#WI6:Q\#&=/8GD^WY0]_+N<:BG?0` M]RN>A<3E9KEU[D`_R"2`YW!'NG"5#:E;;;KA"=J4)V[E'PX#KXZS)M^RTMFM MA<21KV+21CQ&^0-%6N%*IU,1QMK'X"T);`?E.^^^H?\`%''].J:\NW73O$:@ M!=H;8Q:#>NLV>6JSRPIE7JQ:!%*_Y=:^.O)@]Q#F:A/<&R"C]$Q7 M,JTAA'#?5!W?_@YFTQ];5OS.R?8G M*LL7B'YCV(,ONA9KB3^*4@'\EV_;?X$8/CT^'>L[N\K-YT1P/-V]Q@1+,5BA M'OQQ54E*:<$DA->FJS->JF0R\'VULWR6$&IK0^S1.Q?0<.*N1FY/A^G?[5E3RU%B^G?KO71*'/79GU!)*U*356DDO_V3\_ ` end